What's Going On With Geron Stock Today
Portfolio Pulse from Vandana Singh
Geron Corporation (NASDAQ:GERN) submitted a marketing application to the FDA for imetelstat, a treatment for transfusion-dependent anemia in adult patients with low- to intermediate-1 risk myelodysplastic syndromes. The submission is based on positive results from the IMerge Phase 3 trial. Geron has requested a Priority Review and plans to submit a European marketing application in 2H 2023.
June 20, 2023 | 3:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Geron Corporation submitted a marketing application to the FDA for imetelstat, which could lead to potential approval and revenue growth. The stock is up 5.67% on the news.
The submission of the marketing application for imetelstat is a significant milestone for Geron Corporation. If approved, it could lead to revenue growth and increased market share in the treatment of transfusion-dependent anemia. The positive stock price movement of 5.67% indicates that investors are reacting positively to the news.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100